Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Feb 25, 2019 4:48pm
131 Views
Post# 29411168

RE:RE:RE:The Time is Ripe for RVX

RE:RE:RE:The Time is Ripe for RVX"What would the results have been if the Placebo Group was not given Mineral water,  Got to wonder if the results would have been lower for the RRR% in the trial."

There's little doubt, if any, that Vascepa truly elicited remarkable MACE reducing effects in REDUCE-IT. However, as you pointed out there is some question as to whether the choice of placebo (mineral oil by the way, not mineral water) had some degree of deleterious effect in the placebo group. I've expressed my opinion on this numerous times. Mineral oil was a horrible choice. But that ship has sailed. We may never know the full truth as to how Vascepa would have performed in REDUCE-IT when compared to some form of a natural, absorbable vegetable oil instead of mineral oil. For example, Astrazeneca is running a similarly designed STRENGTH trial using corn oil placebo. Corn oil, soybean oil, or some other vegetable oil could have been processed in a way to remove color/taste so as to match Vascepa, or conversely color added to the Vascepa to match placebo. Why Amarin chose differently is mind boggling to me. A horrible decision by the REDUCE-IT clinical steering committe and FDA. With this confound, we may never know for sure how much, if at all, the trial results were padded by mineral oil in the placebo group. So the take home messages are, in my opinion: 1) mineral oil was a horrible choice as placebo and likely increased the placebo group MACE risk a little bit; and 2) Vascepa elicited tremendous benefit in the Vascepa group regardless of the results being partially padded by mineral oil comparator.

BearDownAZ


Bullboard Posts